Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | ENDURANCE: RVD vs KrD for myeloma

Paul Richardson • 28 Jun 2020
EHA 2020
Multiple Myeloma Bortezomib Carfilzomib Dexamethasone Lenalidomide
ENDEAVOUR ENDURANCE

Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses ENDURANCE (NCT01863550), which investigated the use of bortezomib, lenalidomide, and dexamethasone (RVD) compared to carfilzomib, lenalidomide, and dexamethasone (KrD) in newly-diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Paul Richardson

1:35
Novel therapeutic options and quadruplet regimens for newly diagnosed multiple myeloma
Paul Richardson • 29 Sep 2023
2:51
ANCHOR and LIGHTHOUSE trials: melflufen in multiple myeloma
Paul Richardson • 29 Sep 2023
7:24
Session highlights: managing the aging population in myeloma & promising treatment options
Paul Richardson • 29 Sep 2023
2:59
Exploring the potential role of melflufen in myeloma & updates from the LIGHTHOUSE trial
Paul Richardson • 12 May 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals